Dr. David W. Salzman, President, & CEO
“We’re at an exciting point in history and just scratching the surface of our understanding of biological information embedded within sequencing data. By unlocking the power of small RNAs and combining them with data science, we are enabling the devolopment of new therapeutics that treat the underlying drivers of disease,” esclaims David Salzman, founder of sRNAlytics.
Small RNAs regulate health and disease within all living things. Their expression patterns are conserved across species and can classify tissue and cell type of origin. They are found in every type of sample and are extremely stable and easy to extract, making them excellent bioanalytical targets.“The exponential increase in research and publications about small RNA reinforces our excitement, but also highlights significant gaps in today’s approach to harness their power,” Salzman adds.
This is where sRNAlytics steps in. Their patented computational platform is able to discover and test biomarkers from small RNA isoforms with a deterministic measure of the current state of disease. Unlike other approaches, sRNAlytics processes sequencing data with six times greater fidelity, allowing them to annotate over 750K functional small RNA isoforms. This addresses major obstacles found in small RNA research including: inaccuracies in data processing, reference cataloging, and targeted RT-qPCR to detect biomarkers of disease which they call sRNA-TYPEs.
As a result, sRNAlytics’ technology has broad application across all therapeutic areas including oncology, immunology, neurology and all stages of R&D - from preclinical research, clinical development and practice. Through their initial trials and research, they have successfully created a suite of “Research Use Only” tests that have proven to:
• Classify 31 different types of cancer and stratify based on clinical outcome measures
sRNAlytics classifies disease, facilitating the development of new drugs and enabling their effective use to improve patient outcomes
• Classify neurological diseases including Alzheimer’s, Parkinson’s, Huntington’s
• Detect and monitor Huntington’s Disease progression 20 years before symptoms surface
• Monitor drug response in spinal muscle atrophy patients treated with a leading therapeutic
“What excites us the most is our ability to advance the understanding of human health and disease while applying it to the development of new therapies,” says David. “New drug development has a 92% failure rate. Incorporating biomarkers into programs increases success rates by three times,” he continues. To address these market problems, sRNAlytics looks from two perspectives: Drug developers creating new therapies and investing in precision medicineand physicians and patients looking for better diagnostics to understand an individual’s health. “Our portfolio addresses these groups with products and services that simplifies discovering and using small RNA biomarkers.”
sRNA-FIND is their flagship biomarker discovery service. “Our process is easy. Customers provide samples, then the platform discovers biomarkers that can be used to understand the disease as well as drug response,” says Salzman. This process has proven to be effective in helping their customers with patient selection as well as monitoring efficacy during clinical trials.
sRNA-TYPEs are discovered by sRNA-FIND and converted into tests that monitor disease and assist in early and accurate patient diagnosis. sRNA-TYPE HD, for example, detects and monitors Huntington’s Disease 20 years before symptomatic onset. It’s currently under FDA review with the Biomarker Qualification Program, paving the way for other sRNA-TYPE biomarkers to be fast-tracked for approval.
“We are thrilled with the amazing response the science community has had after seeing our data,” says Salzman, “We have developed an extremely powerful classification tool that’s not limited to any specific disease area. Our platform has the long-term potential to be a universal disease classifier for human health, facilitating the development of new drugs and enabling the effective use of them to improve patient outcomes.”